Osimert is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. #Osimert80mg #Osimertinib #AntiCancer #AntiViral #BreastCancer #KidneyCancer #LiverCancer https://iebpharma.com/product/osimert-80mg-osimertinib